Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
52.89B
Market cap52.89B
Price-Earnings ratio
1.67K
Price-Earnings ratio1.67K
Dividend yield
Dividend yield
Average volume
2.25M
Average volume2.25M
High today
$404.58
High today$404.58
Low today
$397.31
Low today$397.31
Open price
$404.58
Open price$404.58
Volume
393.23K
Volume393.23K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

The current Alnylam Pharmaceuticals(ALNY) stock price is $400.59, with a market capitalization of 52.89B. The stock trades at a price-to-earnings (P/E) ratio of 1666.35.

During the trading session on 2025-12-28, Alnylam Pharmaceuticals(ALNY) shares reached a daily high of $404.58 and a low of $397.31. At a current price of $400.59, the stock is +0.8% higher than the low and still -1.0% under the high.

Trading volume for Alnylam Pharmaceuticals(ALNY) stock has reached 393.23K, versus its average volume of 2.25M.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

ALNY News

Simply Wall St 5d
Alnylam Pharmaceuticals Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion

Alnylam Pharmaceuticals (ALNY) just earned a spot in the NASDAQ 100, a move that can channel more passive money into the stock and highlights how far the RNAi p...

Alnylam Pharmaceuticals Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.